Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration

Antibodies validated for use with Bio-Rad’s Celselect Slides™ enumeration stain kits to enable immunostaining of captured circulating tumor cells in liquid biopsy samples.

Biogen turns to telehealth company to boost its postpartum depression drug

As Biogen aims to grow sales of postpartum depression drug Zurzuvae, it’s turning to well-funded telehealth company Talkiatry to boost awareness of and care for

October 8, 2024

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results | Psychedelic Invest

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation

November 13, 2024

Genmab to buy ProfoundBio for $1.8 billion, the latest deal focused on targeted chemotherapies

LONDON — The Danish firm Genmab said Wednesday it would acquire ProfoundBio for $1.8 billion in cash, the latest in a string of 10-figure deals

April 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.